IOVANCE BIOTHERAPEUTICS APPOINTS NEW CHIEF MEDICAL OFFICER
Ticker: IOVA · Form: 8-K · Filed: May 24, 2024 · CIK: 1425205
| Field | Detail |
|---|---|
| Company | Iovance Biotherapeutics, Inc. (IOVA) |
| Form Type | 8-K |
| Filed Date | May 24, 2024 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.000041666 |
| Sentiment | neutral |
Sentiment: neutral
Topics: executive-appointment, personnel, compensation
Related Tickers: IOVA
TL;DR
IOVA names new CMO, Dr. Vogt, with $475K salary + 300K stock options.
AI Summary
On May 23, 2024, IOVANCE BIOTHERAPEUTICS, INC. filed an 8-K report detailing the appointment of Dr. Frederick Vogt as Chief Medical Officer, effective May 20, 2024. Dr. Vogt will receive an annual base salary of $475,000 and is eligible for a discretionary bonus. He will also receive stock options for 300,000 shares of common stock.
Why It Matters
The appointment of a new Chief Medical Officer is a significant leadership change that could impact the company's clinical development strategy and future drug pipeline.
Risk Assessment
Risk Level: medium — Changes in key executive positions, especially the CMO, can signal shifts in strategic direction or potential challenges in clinical development.
Key Numbers
- $475,000 — Annual Base Salary (For new Chief Medical Officer, Dr. Frederick Vogt.)
- 300,000 — Stock Options (Granted to Dr. Frederick Vogt as part of his compensation.)
Key Players & Entities
- IOVANCE BIOTHERAPEUTICS, INC. (company) — Registrant
- Dr. Frederick Vogt (person) — Newly appointed Chief Medical Officer
- $475,000 (dollar_amount) — Annual base salary for Dr. Vogt
- 300,000 (dollar_amount) — Stock options granted to Dr. Vogt
- May 23, 2024 (date) — Date of report filing
- May 20, 2024 (date) — Effective date of Dr. Vogt's appointment
FAQ
Who has been appointed as the new Chief Medical Officer for IOVANCE BIOTHERAPEUTICS, INC.?
Dr. Frederick Vogt has been appointed as the new Chief Medical Officer.
When was Dr. Frederick Vogt's appointment effective?
Dr. Frederick Vogt's appointment was effective May 20, 2024.
What is Dr. Frederick Vogt's annual base salary?
Dr. Frederick Vogt's annual base salary is $475,000.
How many stock options were granted to Dr. Frederick Vogt?
Dr. Frederick Vogt was granted stock options for 300,000 shares of common stock.
What is the filing date of this 8-K report?
This 8-K report was filed on May 23, 2024.
Filing Stats: 462 words · 2 min read · ~2 pages · Grade level 9.1 · Accepted 2024-05-23 20:00:33
Key Financial Figures
- $0.000041666 — h registered Common stock, par value $0.000041666 per value IOVA The Nasdaq Stock Marke
Filing Documents
- tm2415493d1_8k.htm (8-K) — 25KB
- tm2415493d1_ex99-1.htm (EX-99.1) — 25KB
- 0001104659-24-064825.txt ( ) — 227KB
- iova-20240523.xsd (EX-101.SCH) — 3KB
- iova-20240523_lab.xml (EX-101.LAB) — 33KB
- iova-20240523_pre.xml (EX-101.PRE) — 22KB
- tm2415493d1_8k_htm.xml (XML) — 4KB
01. Other Events
Item 8.01. Other Events. On May 23, 2024, Iovance Biotherapeutics, Inc. issued a press release announcing updated clinical data for lifileucel in combination with pembrolizumab in frontline advanced melanoma, as well as translational data, for the upcoming 2024 American Society of Clinical Oncology Annual Meeting to be held May 31 – June 4, 2024 at McCormick Place in Chicago, IL and online. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated by reference herein.
01. Financial
Item 9.01. Financial (d) Exhibits. Exhibit Number Description 99.1 Press Release dated May 23, 2024. 104 Cover Page Interactive Data File, formatted in Inline XBRL and included as Exhibit 101
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Iovance Biotherapeutics, Inc. Dated: May 23, 2024 By: /s/ Frederick G. Vogt Name: Frederick G. Vogt, Ph.D., J.D. Title: Interim CEO and President, and General Counsel